BRM 011
Alternative Names: BRM011Latest Information Update: 28 Dec 2022
At a glance
- Originator Novartis Institutes for BioMedical Research
- Class Antineoplastics; Small molecules
- Mechanism of Action Adenosine triphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA
- 13 Nov 2018 Preclinical trials in Non-small cell lung cancer in USA (unspecified route)
- 13 Nov 2018 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2018)